(Total Views: 334)
Posted On: 11/01/2021 8:53:36 PM
Post# of 30038
Todos Medical Announces 2nd Clinical Trial Site for Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Interim Clinical Trial Data from Phase 2 expected in Q4/21
Nature Neuroscience and Cell Reports publications highlight 3CLpro (Mpro)’s complementary mechanisms of virus replication and immune suppression
New York, NY, and Tel Aviv, ISRAEL, Nov. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and theranostic solutions company, today announced it is now adding the Hillel Yaffe Medical Center as the 2nd clinical trial site in Hadera, Israel for its ongoing Tollovir® Phase 2 randomized, double blind, placebo controlled clinical trial for the treatment of hospitalized COVID-19 patients. Tollovir is an oral 3CL Protease (3CLpro, Main Protease, MPro, Nsp5) antiviral/anti-cytokine therapeutic candidate focused on blocking the 3CL Protease. The Shaare Zedek Medical Center in Jerusalem, Israel was the first site opened in April 2021 having enrolled 30 patients to date. An independent review of interim safety and efficacy data by the Data Safety Monitoring Board (DSMB) of the randomized trial data collected is expected in Q4/2021 that will guide the next steps in the program’s development path towards the therapeutic treatment of COVID-19.
“We believe the addition of a 2nd clinical trial site will accelerate enrollment in our ongoing Phase 2 randomized trial and also expand Tollovir’s clinical footprint,” said Gerald Commissiong, President & CEO of Todos Medical. “The upcoming data analysis is quite significant as it will guide the next steps in our clinical development pathway as we look at the potential use of Tollovir beyond hospitalized patients and potentially evaluating its efficacy in Moderate COVID (pre-hospital) and Long COVID in the future.”
“The recent functional validation of our 3CLpro long ongoing research by two independent groups with publications on 3CLpro in Nature Neuroscience and Cell Reports really provides strong support for the clinical outcomes we have seen in Israel since the pandemic began,” said Dr. Dorit Arad, Chief Scientific Officer of NLC Pharma, the Company’s 3CL protease therapeutic and diagnostics joint venture partner. “We are now evaluating the clinical development implications of these findings on our upcoming Tollovir Phase 2 interim analysis, as well as proposed programs in Moderate COVID and Long Haul trial, as well as looking at pediatric populations who have very few options at the moment. Given that Tollovir is well tolerated, we see the potential to help children suffering from COVID-19.”
https://investor.todosmedical.com/news-events...l-site-for
Interim Clinical Trial Data from Phase 2 expected in Q4/21
Nature Neuroscience and Cell Reports publications highlight 3CLpro (Mpro)’s complementary mechanisms of virus replication and immune suppression
New York, NY, and Tel Aviv, ISRAEL, Nov. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and theranostic solutions company, today announced it is now adding the Hillel Yaffe Medical Center as the 2nd clinical trial site in Hadera, Israel for its ongoing Tollovir® Phase 2 randomized, double blind, placebo controlled clinical trial for the treatment of hospitalized COVID-19 patients. Tollovir is an oral 3CL Protease (3CLpro, Main Protease, MPro, Nsp5) antiviral/anti-cytokine therapeutic candidate focused on blocking the 3CL Protease. The Shaare Zedek Medical Center in Jerusalem, Israel was the first site opened in April 2021 having enrolled 30 patients to date. An independent review of interim safety and efficacy data by the Data Safety Monitoring Board (DSMB) of the randomized trial data collected is expected in Q4/2021 that will guide the next steps in the program’s development path towards the therapeutic treatment of COVID-19.
“We believe the addition of a 2nd clinical trial site will accelerate enrollment in our ongoing Phase 2 randomized trial and also expand Tollovir’s clinical footprint,” said Gerald Commissiong, President & CEO of Todos Medical. “The upcoming data analysis is quite significant as it will guide the next steps in our clinical development pathway as we look at the potential use of Tollovir beyond hospitalized patients and potentially evaluating its efficacy in Moderate COVID (pre-hospital) and Long COVID in the future.”
“The recent functional validation of our 3CLpro long ongoing research by two independent groups with publications on 3CLpro in Nature Neuroscience and Cell Reports really provides strong support for the clinical outcomes we have seen in Israel since the pandemic began,” said Dr. Dorit Arad, Chief Scientific Officer of NLC Pharma, the Company’s 3CL protease therapeutic and diagnostics joint venture partner. “We are now evaluating the clinical development implications of these findings on our upcoming Tollovir Phase 2 interim analysis, as well as proposed programs in Moderate COVID and Long Haul trial, as well as looking at pediatric populations who have very few options at the moment. Given that Tollovir is well tolerated, we see the potential to help children suffering from COVID-19.”
https://investor.todosmedical.com/news-events...l-site-for
(0)
(0)Scroll down for more posts ▼
